← Back to Search

Precision Medicine

OncoTreat for Pancreatic Cancer (HIPPOCRATES Trial)

N/A

Waitlist Available

Led By Rachael A. Safyan, MD

Research Sponsored by Columbia University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 36 months

Awards & highlights

HIPPOCRATES Trial Summary

This trialaims to give personalized treatment to people with advanced pancreatic cancer using a new platform, OncoTreat.

Who is the study for?

This trial is for adults over 18 with advanced pancreatic cancer who haven't started treatment. They should have a life expectancy over 6 months and be able to provide a tissue sample. Those previously treated for pancreatic cancer must have completed therapy more than 6 months ago.Check my eligibility

What is being tested?

The OncoTreat platform is being tested, aiming to offer personalized therapy to patients with untreated metastatic or locally advanced pancreatic adenocarcinoma that cannot be surgically removed.See study design

What are the potential side effects?

Potential side effects of the OncoTreat platform are not specified in the provided information but may include typical reactions related to cancer therapies such as fatigue, nausea, and potential site-specific issues from biopsies.

HIPPOCRATES Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 36 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~36 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants assigned therapy with OncoTreat

HIPPOCRATES Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention ArmExperimental Treatment1 Intervention

Individuals who meet the eligibility criteria based on their provided tissue sample will be followed by the investigators to obtain medical information every 4 weeks. This follow-up will consist of a review of medical records, contact with the participant's treating physician, or personal contact between the participant and the investigators at Columbia University Irving Medical Center (CUIMC). During the study, their tumor tissue will be evaluated to identify medications that may help treat the cancer. The results of these tests will be reviewed by experts on a Precision Medicine Tumor Board (PMTB) and these experts may recommend a specific treatment to the participant or participant's physician.These participants will continue to be followed until death or withdrawal of consent from the study.

Group II: Observation ArmActive Control1 Intervention

Individuals who do not meet the eligibility criteria based on their provided tissue sample will be provided follow-up with their treating physicians up to every 4 weeks to gather clinical information related to their disease.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor

1,431 Previous Clinical Trials

2,460,801 Total Patients Enrolled

Rachael A. Safyan, MDPrincipal InvestigatorColumbia University

1 Previous Clinical Trials

36 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants is the trial currently recruiting?

"Affirmative. Clinicaltrials.gov’s records display that this research program, which first appeared on August 10th 2018, is actively seeking participants. The goal is to secure 30 patients from two different sites for the duration of the trial."

Answered by AI

Are there still available spots in this research endeavor?

"Per clinicaltrials.gov, this medical trial is actively recruiting patients. The original posting date of the study was August 10th 2018 and it has since been updated on November 29th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

RNA Precision Oncology in Advanced Pancreatic Cancer

Gulam Manji 2018. "RNA Precision Oncology in Advanced Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04476537.